$0.53 EPS Expected for Teva Pharmaceutical Industries Ltd (TEVA) This Quarter

Brokerages forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report earnings of $0.53 per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The highest EPS estimate is $0.57 and the lowest is $0.45. Teva Pharmaceutical Industries posted earnings per share of $0.93 in the same quarter last year, which suggests a negative year over year growth rate of 43%. The business is expected to announce its next earnings results on Thursday, February 14th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.80 per share for the current financial year, with EPS estimates ranging from $2.71 to $3.03. For the next year, analysts anticipate that the firm will post earnings of $2.83 per share, with EPS estimates ranging from $2.65 to $3.10. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 1st. The company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The firm had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.54 billion. During the same quarter in the previous year, the business posted $1.00 EPS. The company’s quarterly revenue was down 19.4% on a year-over-year basis.

TEVA has been the subject of several recent analyst reports. Goldman Sachs Group raised Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price target for the company in a research report on Monday, October 1st. Credit Suisse Group lowered Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $25.00 to $23.00 in a research report on Friday, September 7th. Leerink Swann raised Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating and lifted their price target for the stock from $16.00 to $24.00 in a research report on Monday, October 1st. Cantor Fitzgerald set a $25.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, September 14th. Finally, Mizuho lifted their price target on Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Five equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $21.58.

In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Iris Beck Codner sold 4,165 shares of the business’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $22.70, for a total value of $94,545.50. Following the completion of the transaction, the executive vice president now directly owns 8,290 shares of the company’s stock, valued at approximately $188,183. The disclosure for this sale can be found here. In the last three months, insiders sold 10,350 shares of company stock valued at $239,430. 0.43% of the stock is owned by insiders.

Large investors have recently modified their holdings of the business. CWM LLC raised its position in Teva Pharmaceutical Industries by 315,000.0% in the 3rd quarter. CWM LLC now owns 6,302 shares of the company’s stock worth $136,000 after buying an additional 6,300 shares during the last quarter. Wealthstreet Investment Advisors LLC purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $200,000. MAI Capital Management purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $204,000. Greenleaf Trust purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $215,000. Finally, Rehmann Capital Advisory Group increased its position in shares of Teva Pharmaceutical Industries by 136.2% during the 2nd quarter. Rehmann Capital Advisory Group now owns 9,019 shares of the company’s stock valued at $219,000 after purchasing an additional 5,201 shares during the last quarter. 65.10% of the stock is owned by institutional investors and hedge funds.

Shares of TEVA stock opened at $22.85 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. The firm has a market cap of $22.97 billion, a PE ratio of 5.81, a price-to-earnings-growth ratio of 1.85 and a beta of 0.77. Teva Pharmaceutical Industries has a 12 month low of $11.41 and a 12 month high of $25.96.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: How Do You Calculate Return on Investment (ROI)?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply